Identification of key genes and specific pathways potentially involved in androgen-independent, mitoxantrone-resistant prostate cancer

BACKGROUND: Resistance to mitoxantrone (MTX), an anthracenedione antineoplastic agent used in advanced and metastatic androgen-refractory prostate cancer (PCa), seriously limits therapeutic success. METHODS: Xenografts from two human PCa cell lines (VCaP and CWR22) were established in male severe co...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Sha, Jiang, Lili, Wang, Liuyan, Wang, Lingli, Zhang, Cong, Ma, Yu, Huang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322516/
https://www.ncbi.nlm.nih.gov/pubmed/30655694
http://dx.doi.org/10.2147/CMAR.S179467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322516/
https://www.ncbi.nlm.nih.gov/pubmed/30655694
http://dx.doi.org/10.2147/CMAR.S179467

Ejemplares similares